Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

CLDN18.2-targeted CAR-T immunotherapy

DRUG CLASS:

CLDN18.2-targeted CAR-T immunotherapy

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

CLDN18.2 positive	Gastric Cancer	CLDN18.2 positive	Gastric Cancer	CT041 Sensitive: C2 – Inclusion Criteria CT041 Sensitive : C2	CT041 Sensitive: C2 – Inclusion Criteria CT041 Sensitive : C2
CLDN18.2 positive	Pancreatic Ductal Adenocarcinoma	CLDN18.2 positive	Pancreatic Ductal Adenocarcinoma	CT041 Sensitive: C2 – Inclusion Criteria CT041 Sensitive : C2	CT041 Sensitive: C2 – Inclusion Criteria CT041 Sensitive : C2
CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	CT041 Sensitive: C2 – Inclusion Criteria CT041 Sensitive : C2	CT041 Sensitive: C2 – Inclusion Criteria CT041 Sensitive : C2
CLDN18.2 expression	Pancreatic Cancer	CLDN18.2 expression	Pancreatic Cancer	CT041 Sensitive: C4 – Case Studies CT041 Sensitive : C4	CT041 Sensitive: C4 – Case Studies CT041 Sensitive : C4
CLDN18.2 expression	Pancreatic Cancer	CLDN18.2 expression	Pancreatic Cancer	IBI-345 Sensitive: C4 – Case Studies IBI-345 Sensitive : C4	IBI-345 Sensitive: C4 – Case Studies IBI-345 Sensitive : C4
CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	IBI-345 Sensitive: C4 – Case Studies IBI-345 Sensitive : C4	IBI-345 Sensitive: C4 – Case Studies IBI-345 Sensitive : C4
CLDN18.2 expression	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 expression	Gastroesophageal Junction Adenocarcinoma	IBI-345 Sensitive: C4 – Case Studies IBI-345 Sensitive : C4	IBI-345 Sensitive: C4 – Case Studies IBI-345 Sensitive : C4
CLDN18.2 positive	Gastric Cancer	CLDN18.2 positive	Gastric Cancer	CLDN18.2-targeted CAR-T immunotherapy Sensitive: D – Preclinical CLDN18.2-targeted CAR-T immunotherapy Sensitive : D	CLDN18.2-targeted CAR-T immunotherapy Sensitive: D – Preclinical CLDN18.2-targeted CAR-T immunotherapy Sensitive : D